![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 290, Issue 1, 158-169, July 1999
GlaxoWellcome S.p.A., Medicines Research Centre, Department of
Pharmacology, Verona, Italy
Central sensitization is a condition of enhanced excitability of spinal
cord neurons that contributes to the exaggerated pain sensation
associated with chronic tissue or nerve injury.
N-methyl-D-aspartate (NMDA) receptors
are thought to play a key role in central sensitization. We have tested
this hypothesis by characterizing in vitro and in vivo a novel
antagonist of the NMDA receptor acting on its glycine site, GV196771A.
GV196771A exhibited an elevated affinity for the NMDA glycine binding
site in rat cerebral cortex membranes (pKi = 7.56). Moreover, GV196771A competitively and potently antagonized the
activation of NMDA receptors produced by glycine in the presence of
NMDA in primary cultures of cortical, spinal, and hippocampal neurons
(pKB = 7.46, 8.04, and 7.86, respectively).
In isolated baby rat spinal cords, 10 µM GV196771A depressed wind-up,
an electrical correlate of central sensitization. The
antihyperalgesic properties of GV196771A were studied in a model of
chronic constriction injury (CCI) of the rat sciatic nerve and in the
mice formalin test. In the CCI model GV196771A (3 mg/kg twice a day
p.o.), administered before and then for 10 days after nerve ligature,
blocked the development of thermal hyperalgesia. Moreover, GV196771A
(1-10 mg/kg p.o.) reversed the hyperalgesia when tested after the
establishment of the CCI-induced hyperalgesia. In the formalin test
GV196771A (0.1-10 mg/kg p.o.) dose-dependently reduced the duration of
the licking time of the late phase. These antihyperalgesic properties were not accompanied by development of tolerance. These observations strengthen the view that NMDA receptors play a key role in the events
underlying plastic phenomena, including hyperalgesia. Moreover, antagonists of the NMDA glycine site receptor could represent a new
analgesic class, effective in conditions not sensitive to classical opioids.
This article has been cited by other articles:
![]() |
C. Villmann and C.-M. Becker On the Hypes and Falls in Neuroprotection: Targeting the NMDA Receptor Neuroscientist, December 1, 2007; 13(6): 594 - 615. [Abstract] [PDF] |
||||
![]() |
A. M. Abeles, M. H. Pillinger, B. M. Solitar, and M. Abeles Narrative Review: The Pathophysiology of Fibromyalgia Ann Intern Med, May 15, 2007; 146(10): 726 - 734. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Polli, T. M. Baughman, J. E. Humphreys, K. H. Jordan, A. L. Mote, L. O. Webster, R. J. Barnaby, G. Vitulli, L. Bertolotti, K. D. Read, et al. THE SYSTEMIC EXPOSURE OF AN N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST IS LIMITED IN MICE BY THE P-GLYCOPROTEIN AND BREAST CANCER RESISTANCE PROTEIN EFFLUX TRANSPORTERS Drug Metab. Dispos., July 1, 2004; 32(7): 722 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Villetti, M. Bergamaschi, F. Bassani, P. T. Bolzoni, M. Maiorino, C. Pietra, I. Rondelli, P. Chamiot-Clerc, M. Simonato, and M. Barbieri Antinociceptive Activity of the N-Methyl-D-aspartate Receptor Antagonist N-(2-Indanyl)-glycinamide Hydrochloride (CHF3381) in Experimental Models of Inflammatory and Neuropathic Pain J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 804 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Wallace, M. C. Rowbotham, N. P. Katz, R. H. Dworkin, R. M. Dotson, B. S. Galer, R. L. Rauck, M. M. Backonja, S. N. Quessy, and P. D. Meisner A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain Neurology, December 10, 2002; 59(11): 1694 - 1700. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bridges, S. W. N. Thompson, and A. S. C. Rice Mechanisms of neuropathic pain Br. J. Anaesth., July 1, 2001; 87(1): 12 - 26. [Abstract] [Full Text] [PDF] |
||||